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Medical and social outcome in adolescents with end-stage renal failure.
Clinical information was collected on 118 adolescents who developed
ESRF at age 143 months or older and were treated between 1966 and
1986 at the Toronto Hospital for Sick Children. The cumulative survival
rate in transplanted patients (N = 109) was 80.1% after 15 years.
Survival rates after four years were 93.9% in transplanted and 46.9% in
nontranspianted patients (P < 0.001). No patient receiving dialysis
alone (N = 9) was followed longer than four years. Nine patients
received three transplants and had an 89% survival rate. Six of these
had a functioning graft at end of the follow-up. The cumulative survival
of the entire group was 76.4% at eighteen years. Forty-two (35.6%)
patients had a height below the third percentile. Functional status
obtained by a stmctured telephone interview with a member of the
present treating nephrology service was good (G) or excellent (E) for
66.7% of all patients (73.5% of transplant patients (N = 68) and 45% of
dialysis patients (N = 20). Hemodialysis patients functioned less well
[25% G/E (N = 12)] than peritoneal dialysis patients [75% G/E (N = 8)].
Most patients achieved an appropriate level of formal education al-
though more slowly than normal adolescents. Only 11 patients were
neither enrolled in an educational institution nor employed. We con-
clude that aggressive treatment for adolescents with ESRF is an
appropriate application of health care resources.
Advances in therapy for renal failure have resulted in in-
creased survival rates compared to earlier years [1]. Evaluation
of efficacy of treatment requires assessment of both survival
and quality of life obtained from the treatment [21. Many reports
indicate an increased quality of life or rehabilitation for trans-
plant patients as compared to dialyzed patients [3—81. Adoles-
cents approaching physical maturity and with no other health
problems should have the potential for excellent rehabilitation.
Methods
Information was obtained on all 118 adolescents (children
aged between 143 months and 239 months) presenting with
end-stage renal failure (ESRF) to the dialysis and transplanta-
tion service at the Hospital for Sick Children in Toronto from
the inception of the program in 1966 until December 1986.
Survival and functional status were reviewed. An abstraction
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form suitable for entry into a computer was completed by the
authors (JR and LS) for each eligible patient. Information was
obtained from several sources: the medical record of each
patient; computerized data base of the Metropolitan Organ
Retrieval and Exchange (MORE) program located at the Tor-
onto General Hospital; and a telephone interview with the
patient's present physician or other informed caregiver. A
structured questionnaire was utilized for telephone interviews
and was administered by the same author (JR) in all cases.
Information collected included: sex, age at onset of ESRF
and end of follow-up; primary and secondary diagnoses; treat-
ment and duration; complications of the ESRF (for example,
serious infection, pericarditis, hypertensive encephalopathy);
height at the beginning of therapy and at follow-up; and vital
status and cause of death at follow-up (December 31, 1986).
Functional evaluation included: educational level achieved;
ability to care for self as judged by whether living alone or with
family; employment or availability for employment; marital
status; achievement of parenthood, and opinion of the caregiver
on general adjustment. Functioning status was categorized as
follows: poor (unable to care for self, living with family or
institutionalized, drug or alcohol addiction); fair (can do some
things by self, but socially or financially dependent on family,
not employed and/or behind in school); good (in school or
employed but living with family); excellent (social and financial
independence, employed or studying, married, children). Data
were analyzed using the SAS statistical package [9]. The level
of statistical significance was accepted at a 5% probability or
less. Cumulative survival rates were compared by the log rank
test [10].
Results
Demographics
One hundred and twenty-three case records were reviewed.
Of these, 118 adolescents were between 143 months and 239
months when ESRF therapy was initiated. Four patients were
disqualified because they were younger at entry. One, a dwarf,
accepted because of size, was too old. Only two of the 118
patients studied were lost to follow-up. Up to date case records
were unavailable for three patients, but information was ob-
tained from other sources (usually telephone contact with
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Table 1. Cause of death
Cause N %
Infect ion 7 35
Hyperkalemia 4 20
Hemorrhage 3 15
Cardiac 3 15
Accident 2 10
Cancer 1 5
Total 20 100
nephrologist). Follow-up ranged from 1 to 218 months (7.9
0.2 years).
At onset of ESRF, 79 (67%) were 143 months to 191 months
of age and 39 (33%) were 192 to 239 months (mean 14.9 0.2
years). At the follow-up, their mean age was 22.1 0.4 years.
The male to female ratio was 0.97 (58/60). Twelve of the male
patients (10.2% of total population) had a diagnosis of Alport's
syndrome (X-linked hereditary nephritis). Other diagnostic
categories included primary glomerulopathies (39%) and pyelo-
nephritis (including reflux nephropathy, 31%). Congenital dis-
ease accounted for 18%, and in 1% the primary renal diagnosis
was unknown. No patient presented with diabetes mellitus
although one patient developed glucose intolerance during
therapy.
Treatment modality
Most patients received two or more types of therapy during
the course of their illness. Eighty-nine (75.4%) patients were
treated with hemodialysis at some time in their course, 56
(47.5%) with peritoneal dialysis (either CAPD, CCPD, or IPD)
and 109 (92.4%) received at least one renal transplant. Trans-
plantation was the initial mode of renal replacement therapy in
10 patients, and 34 patients received more than one transplant.
Nine patients received three transplants over a period of
follow-up ranging from 71 to 204 months (10.9 3.4 years).
Eight of these patients survived to the end of the follow-up. The
single death occurred in the third postoperative transplant
period and was due to hemorrhage after subclavian line inser-
tion.
Mortality and morbidity
At the follow-up 20 (17%) patients had died (Table 1).
Infection was the most common cause of death (7 patients,
35%). Four patients (3 dialysis and 1 recent transplant) died of
documented or presumed hyperkalemia (sudden electrome-
chanical dissociation). Deliberate noncompliance/suicide was
suspected in at least two of the deaths in the dialysis patients
(both had rejected transplants). Hemorrhage and cardiac arrest
each caused the death of three patients. Two patients died from
accidental trauma (motor vehicle accident and fall). Three
patients on long-term immunosuppressive therapy developed
malignancy. One of these patients died (squamous cell carci-
noma of the lip) and one was terminally ill with carcinoma of the
cervix at follow-up. The presenting renal disease had no signif-
icant impact on mortality (P > 0.05).
Cumulative survival for the entire patient population was
76.4% at 18 years (Fig. 1). The four-year cumulative survival
after renal transplantation was 93.9% compared to 46.9% in the
nontransplanted group (P < 0.001; Fig. 2). No nontransplanted
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Fig. 1. Cumulative survival after treatment of ESRF in adolescents. A
total of 76.4% survived 18 years. The entire group was 118 patients.
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Fig. 2. Comparison of survival rates in transplanted and nontrans-
planted patients. Adolescents who received transplants survived sig-
nificantly longer than nontransplanted adolescents. Nine patients re-
ceived no transplant (*), 109 received at least one transplant (t). P <
0.001.
patient was followed longer than four years. Patient entry
groups were arbitrarily Separated into consecutive five-year
periods for analysis. The five-year cumulative survival was
88.9% in period 1 (Dec. 1966 to Nov. 1971), 92.9% in period 2
(Dec. 1971 to Nov. 1976), 83.7% in period 3 (Dec. 1976 to Nov.
1981), and 93.9% after four years in period 4 (Dec. 1981 to Dec.
1986) (Table 2). Period 1 maintained an 88.9% 15-year survival
rate, whereas period 2 fell to 67.9% in 15 years and period 3 was
81.3% after 10 years. Period 4 was too short to obtain a
long-term survival rate. Table 3 demonstrates the survival of
patients receiving from zero to three transplants.
Thirty patients (25.4%) presented with other significant med-
ical conditions (Table 4). Four patients had primary cardiac
disease on presentation [myocardial fibrosis (1), high-output
congestive failure (2), and valvular heart disease (1)]. Two of
these patients died. Eleven patients presented with various
systemic-disorders causing the renal failure [systemic lupus (4),
hemolytic uremic syndrome (4), Henoch-Schönlein purpura (1),
infantile pblycystic kidney with hepatic fibrosis (1), and cysti-
nosis (1)1. Three of these eleven died. Pre-existing neurologic
disease [mental retardation/psychosis (4), primary seizure dis-
order (2), and cystic intracerebral lesion with 2 subsequent
hemorrhages (1)], occurred in seven, of whom one died. Two
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Table 2. Cumulative survival rates according to the period of entry
(P> 0.5, log rank test)
Year
1967—1971 1972—1976 1977—1981 1982—1986
(N = 9) (N = 28) (N = 43) (N = 38)
%
Table 4. Mortality rate in ESRF patients with additional disease
Cause Cases Deaths %
Cardiac 4 2 50
Systemic II 3 27.3
Neurologic 7 1 14.3
COPD 2 1 50
Scoliosis 4 0 0
Other 2 0 0
Total 30 7 23.3
1 100 96.4 95.4 97.!
2 100 92.9 93.0 93.9
3 88.9 92.9 93.0 93.9
4 88.9 92.9 88.4 93.9
5 88.9 92.9 83.7
6 88.9 85.7 81.3
7 88.9 75.0 81.3
8 88.9 71.4 81.3
9 88.9 71.4 81.3
10 88.9 67.9 81.3
11 88.9 67.9
12 88.9 67.9
13 88.9 67.9
14 88.9 67.9
15 88.9 67.9
16 88.9
17 88.9
18 88.9
Patients with cardiac and chest disease experienced a proportionately
larger number of deaths than other groups.
The cumulative survival of each group is illustrated as a percent of
the total in each group surviving over time of follow-up. Entry periods
were arbitarily divided into five year time spans. The difference in
survival between periods of entry is not significant.
Table 5. ESRD therapy at the end of follow-up
Therapy N %
Functioning transplant 73 61.9
Hemodialysis 13 11.0
CAPD 6 5.1
IPD 2 1.7
Recovered renal function 2 1.7
Lost to follow-up 2 1.7
Dead 20 17.0
Table 3. Cumulative survival rates according to the number of
transplants received (P < 0.001, log rank test)
No transp. Transp.(N=9) (N=75)
Year %
100
100
96.0
88.0
88.0
76.3
76.3
76.3
76.3
76.3
76.3
76.3
76.3
76.3
76.3
100
100
100
100
100
100
88.9
88.9
88.9
88.9
88.9
88.9
88.9
88.9
88.9
88.9
88.9
88.9
Follow-up status
infection (peritonitis, line sepsis, pneumonia) in 20 (17%), 13 of
which were life threatening and 7 fatal; cardiac in 10 (8.5%)
(pericarditis in 5 and cardiac arrest in 5; 3 were fatal); neuro-
logical in 8 (6.8%) (seizures secondary to hypertensive enceph-
alopathy or uremia in 5, intracerebral hemorrhage in 2(1 death),
and 1 transient hemiparesis); and hemorrhage from line inser-
tion (I, fatal). The remaining deaths not classified as complica-
TranS) Transp.
62.5 98.6
2 46.9 95.8
4 46:9 95:8
tions included hyperkalemia (4), accident (2), cancer (1), and
gastrointestinal hemorrhage (1) in a patient with hepatic fibrosis
due to infantile polycystic kidney disease. Eighty-one patients
5 93.8 (68.6%) were free of significant complications throughout their
6 91.7 entire course.
7 87.0
8 84.4
10 The ages of this group of patients at December 1986 ranged
11 80.5 from 12 to 37 years (mean 22.1 0.4). Sixty-seven percent of
12 80,5
l3
0.5
15 80:5
the group were under the age of 24 years. Seventy-three
patients (62%) had a functioning transplant at follow-up. Fifty-
three patients (70.7%) of the 75 receiving only one transplant
16 80.5 continued to have a functioning transplant at the end of follow-
17 80.5
18 80.5
up. Thirteen patients (11%) were on hemodialysis, and eight
(7%) were on various forms of peritoneal dialysis (Table 5).
Twenty patients had died, two were lost to follow-up and twoA significant difference in survival occurred between patients receiv-
ing no transplants and patients receiving one or more transplants. patients with lupus had recovered their renal function. Exclud-
ing deaths and loss to follow-up, 77.7% (73 of 94) of surviving
patients were living with a functioning graft.
patients had chronic obstructive pulmonary disease (one with Forty-two of the 99 patients (42.4%, or 35.6% of total group)
prune belly syndrome and scoliosis, one idiopathic). One of on whom height information was available failed to reach a
these two patients died of pneumonia after six years of therapy height above the third percentile at the end of follow-up. Poor
for ESRF. None of the patients with other pre-existing condi- growth was associated with age at onset of ESRF. The mean
tions [scoliosis (4), pseudohermaphrodism (1), and rubella age at onset of ESRF in those under the third percentile was
syndrome (1)] died. Thirteen of 88 (14,8%) patients who did not 171.5 3.3 months versus 183.7 3.2 months for those who
have additional disease died during follow-up, were above the third percentile (P < 0.01 Student's t-test).
Thirty-nine direct complications of ESRF or therapy were There was a tendency for an association with a diagnosis of
documented in 37 (3 1.4%) patients. These complications were: Alport's syndrome, or congenital renal disease (P = 0.059, chi
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Fig. 3. Education level at end of follow-up according to age groups.
Education level is defined by the entry into each system, public (U),
high () or post-secondary (EJ), and not by successful graduation
from the level. The majority of patients achieve at least some high
school education.
square test). Despite immediate transplantation without a pe-
riod of dialysis in 10 patients who presumably experienced a
long slow course of chronic renal insufficiency prior to ESRF,
six still experienced poor growth.
Information on functional status was obtained for 90 of the 96
known surviving patients (94%). At the end of the follow-up 62
(68.9%) were living with family members and 26 (28.9%) were
living either on their own (17) or with a spouse (9). Four patients
have become parents. One patient was institutionalized. The
current living arrangement of one patient was unknown.
Information on school achievement was available on 80
patients (83%). Figure 3 shows the educational level achieved
with respect to the various current age groups. The greater than
20 age group had a larger percentage of people with only public
school education than the 16 to 20 age group. In each age group,
there was some educational delay. However, only 11 (13.8%)
patients were neither enrolled in an educational program nor
employed.
Functional outcome as defined subjectively by the caregiver
was highest in the transplanted group (Fig. 4). Fifty of 68
(73.5%) in the transplanted group had a good or excellent level
of function compared to 9 of 20 (45%) patients on dialysis (P <
0.05). However, when type of dialysis therapy was considered,
only 3 of 12 (25%) of the hemodialysis patients had a good or
excellent level of function compared to 6 of 8 patients (75%) on
peritoneal dialysis. The remaining two assessed patients had
recovered renal function [functional status fair (1) and excellent
(1)].
Discussion
Three hundred and seventy-three Canadian children ages 0 to
15 were treated for ESRF between 1981 and 1989 [11]. The
Canadian Organ Replacement Register (CORR) records infor-
mation on all patients with ESRF in Canada. The Toronto
Hospital for Sick Children established the first Canadian ESRF
treatment center for children and currently follows 88 patients
(personal communication, R. Poole). The long period of oper-
ation provides an opportunity to evaluate the long-term out-
come of treatment.
0
Transplant Hemodialysis CAPD IPO No treatment
Treatment modality
Fig. 4. Functional status as related to treatment modality in ESRF.
Functional status (assessed by caregiver) is indicated by: (U) poor;() fair; (El) good; () excellent. Each treatment modality
group (at end of follow-up) was assessed separately. The majority of
patients fell into the good to excellent group.
The smaller number of patients in the older age group may be
explained by the pediatric nature of the hospital. Patients in
older age groups are undoubtedly being treated in adult hospi-
tals. There was a slight preponderance of females (56.6% vs.
43.4%) in patients without Alport's syndrome. The two major
diagnoses of ESRF in adolescents, glomerulonephritis (39%)
and pyelonephritis (31.4%), resembles adult populations [12,
13]. No patients with ESRF from diabetes mellitus were seen.
Treatment modality affected survival rate. The cumulative
survival rate in our nontranspianted group was worse (46.9%)
than in our transplanted group (93.9%) followed over a four
year period (P <0.001). A strong selection bias toward aggres-
sive transplantation undoubtedly influenced results. Failure to
transplant in the nontransplanted patients was usually due to
the presence of other medical conditions that made transplan-
tation an inappropriate form of treatment. Eighteen percent (45
of 252) of transplants in pediatric patients in Canada between
1981 and 1989 were from a living related donor. The corre-
sponding figure for Ontario in 1989 was 25% (3 of 12) [11].
Transplantation was a very well tolerated form of treatment
with an 18-year cumulative survival rate of 80.1%. Patients
receiving one, two and three transplants had a 15-year cumu-
lative survival rate of 80.5%, 76.3% and 88.9%, respectively.
Potter et al have reported a five-year pediatric patient survival
after living-related donor transplant of 93% and after cadaver
donor transplant of 75% [14]. Eight of nine patients in our study
who received three transplants each still survived at the end of
a 15 year follow-up, and six of these patients had a functioning
transplant. This experience with multiple transplants is also
similar to that of Potter et al. This excellent survival and
transplant function indicates that repeat transplantation pro-
vides a reasonable option for those who have experienced more
than one failed transplant.
In all four periods, the total five year survival exceeded 88%.
This statistic compares well to the published survival rate of
82.8% (309 of 373) for children age 0 to 15 years reported to
CORR between 1981 and 1989 [111. Length of follow-up,
however, is not reported. Najerian et al reported similar sur-
vival (84%, 2 months to 18 years follow-up) [15]. Potter et at
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reported survival for pediatric patients as 93% after an average
of ten months of dialysis [16]. In contrast, the European
Dialysis and Transplantation Association Registry (EDTAR),
which has been collecting information since 1972, reported a
75% survival rate in 5482 patients treated up to 1985 [171. The
survival of these adolescents also compares favorably to pub-
lished data on adults. A study consisting of 4661 adults demon-
strated a 39.6% survival rate of dialysis patients over a 4.5 year
period [11.
The cumulative survival for the different entry periods were
not significantly different (Table 2), although the survival in
period 2 did tend to be lower, possibly reflecting less stringent
selection than period 1 and less clinical experience than periods
3 and 4. Not surprisingly, patients with significant associated
cardiac or systemic disease during treatment tended to have a
higher mortality rate than those with no other disease (50%
cardiac, 27% systemic) (Table 4). In the isolated renal failure
group only 14.8% of the patients died.
Causes of death differed from reported Canadian figures
(CORR) [111 with a higher proportion of deaths from infection
in our group (35% vs. 10.9%) and a lower proportion of cardiac
deaths (15% vs. 3 1.3%). The most likely explanation for this
observation is the difference in the time periods described. The
incidence of fatal infection in our series declined from 11% in
periods 1 and 2, and 4.7% in period 3 to only 2.6% between 1981
and 1986. The CORR encompasses 1981 to 1989. The apparent
improvement in mortality from infections may be due to less
aggressive immunosuppression, more effective antibiotic ther-
apy, or simply the shorter period of follow-up. The high
proportion of infection-related deaths is similar to the 49 to 55%
reported by Potter et a! [14, 16]. EDTAR reports 17.2% of
pediatric deaths between 1981 and 1985 were due to infection
[17].
Growth retardation remains a problem with 35.6% of our
patients, remaining below the third percentile at follow-up. This
closely resembles the experience of Kleinknecht et at, who
reported that one third of a population of children followed on
chronic dialysis therapy exhibited severe growth retardation
[18]. Initial growth retardation affected ultimate outcome, as
although these children often did show a period of accelerated
growth this was not adequate to produce normal height [18].
Similar experience is reported by Foreman and Chan [19].
Analysis of our data demonstrated an association between a
diagnosis of Alport's syndrome or congenital renal disease and
height that approached statistical significance (chi-square, P =
0.059) as well as a significantly younger mean age of onset of
ESRF in growth retarded children. This is not surprising as
growth retardation would be expected with a long period of
renal insufficiency or onset of ESRF prior to the adolescent
growth spurt. Six of 10 patients who were transplanted imme-
diately without a period of dialysis still remained below the
third percentile at the end of follow-up. Although growth has
been reported to be better with transplant than dialysis [11],
these data demonstrate a problem with growth in the transplant
group as well. A comparison of growth in dialysis versus
transplant periods is not possible in this group as most patients
received multiple therapies and the height data was abstracted
only at the beginning of therapy and at the end of the follow-up.
Results for quality of life were equally as encouraging as
survival. At follow-up, 73.5% of the transplant patients had a
good or excellent level of function compared to 45% of patients
on dialysis (P < 0.05). This compares well to experience in
adults [20-23]. Functional outcome was less satisfactory for
hemodialysis patients (25% GtE) than for peritoneal dialysis
patients (75% G/E), however, the number of patients in each
group was quite small. The difference in outcome between the
two modalities of dialysis may be related to selection criteria
determining entry into each group rather than to the character-
istics of the dialysis therapy itself. Peritoneal dialysis is usually
performed at home either as CAPD (N = 6) or intermittent
peritoneal dialysis (N = 2). The procedure can be performed
either by patient or family. The good functional outcome in this
group probably represents the combination of greater indepen-
dence, flexibility of scheduling therapy, and selection of pa-
tients and families likely to be capable of this level of compli-
ance. The poorer outcome on hemodialysis may reflect
selection of less compliant or capable patients (less ability to
learn, poor parental support, availability for hemodialysis dur-
ing the day), or may reflect rehabilitation difficulties associated
with rigid treatment schedules (obligatory absence from school
due to dialysis schedule). Difficulty in obtaining vascular access
may have contributed also to increased morbidity. Not infre-
quently this problem has prompted the selection of peritoneal
dialysis as treatment of choice for children at HSC in recent
years. Surprisingly, poor functional outcome status was not
correlated to growth retardation. Recently, improved results in
growth have been achieved with the use of recombinant human
growth hormone and erythropoietin [241. This treatment was
not available for these patients.
The patients in our study were divided into three age groups
for the analysis of their education level. A large percentage
(78.8%) of the patients had achieved at least some secondary
education. However, this achievement occurred later than
normal revealing a somewhat slower pace than healthy individ-
uals. A larger percentage of the oldest group had only a public
school education, which may reflect the decreased expectation
for survival and quality of life of the earliest patients and their
families. The employment/active education rate (90%) for trans-
planted ESRF patients in this study was better than that
reported in other studies involving adults; 74% able to work [6],
47 to 54% working [4, 6, 23]. Unfortunately the employment
status of the nontransplanted patients in this study was largely
unknown so that the comparison of outcome in this group could
not be performed. The early demise of this group makes
employment unlikely.
Conclusion
The survival rate and functional outcome in adolescents
treated for ESRF over the 20 year period between 1966 and
1986 was impressive. This was achieved with a very low
morbidity rate. Survival and quality of life were superior in
patients who were successfully transplanted. Treatment modal-
ity was selected on clinical grounds and we acknowledge a
strong bias toward transplantation. Nevertheless, we believe
that the data support the conclusion that transplantation is
especially important in adolescents as it allows the potential for
full rehabilitation and for the resumption of an unencumbered
lifestyle. In those patients who are not transplantable, dialysis
treatment modalities that allow the greatest independence and
flexibility result in the best functional outcome. Adolescents
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with ESRF should be treated aggressively with an early trans-
plant to minimize the burdens of dialysis and to maximize the
potential benefits of transplantation.
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